Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Coherus Oncology, Inc. (industry) · CHRS — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
145actual
Sites
23
Countries
Singapore, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-04-22 | actual | When the study began enrolling |
| Primary completion | 2025-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-05 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
Interventions
- Drug: CHS-388 — also filed as Casdozokitug
- Drug: Pembrolizumab — also filed as Keytruda®
- Drug: Toripalimab — also filed as Loqtorzi®
Primary outcomes
what the primary-completion date above is the date OF[Part A] Dose Limiting Toxicity (DLT)
measured Assessed during first 28 days of treatment
[Part B] Confirmed objective response rate (ORR)
measured Up to 24 months
[Part C] DLT
measured Assessed during first 21 days of treatment
[Part C] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)
measured Up to 24 months
[Part C -NSCLC Cohort] Objective response rate (ORR)
measured Up to 24 months
[Part D] Objective response rate (ORR)
measured Up to 24 months
Permalink · CHRS's whole pipeline · Catalyst calendar · Every registered study · What changed